NON-ANTIBIOTIC PRODUCT FROM CHEMAPHOR INC. ENHANCES INNATE IMMUNITY IN FISH
Opens possibilities for use as a low risk, non-antibiotic, prophylactic, natural health product for maintaining health and helping protect against infectious diseases
OTTAWA, ON., June 9, 2011 - Recently released research has shown that immunity in fish is enhanced when fed Chemaphor's proprietary mixture of fully oxidized carotenoids. MORE>>
SYNCAPSE GEARS UP FOR RAPID GROWTH WITH ADDITIONS TO EXECUTIVE TEAM
Five New Appointments Will Drive Growth and Deliver Social Media Management Solutions for Enterprise Clients
TORONTO, ONTARIO and NEW YORK, NEW YORK--(Marketwire - June 1, 2011) - Syncapse Corp., a global leader in social media management for large enterprise, announced today five new additions to its executive team, signaling its intention for rapid growth heading into the second half of 2011. MORE>>
CYNAPSUS THERAPEUTICS TO PRESENT AT BIOFINANCE 2011 CONFERENCE
TORONTO, ONTARIO--(Marketwire - May 31, 2011) - Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, announced today that Anthony Giovinazzo, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2011 Conference, being held this week in Toronto. Mr. Giovinazzo will be speaking tomorrow (Wednesday, June 1st) at 3:00 p.m., at the St. Andrew's Club & Conference Centre, 150 King Street West. MORE>>
TORONTO, ONTARIO--(Marketwire - May 31, 2011) - Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, announced today that Anthony Giovinazzo, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2011 Conference, being held this week in Toronto. Mr. Giovinazzo will be speaking tomorrow (Wednesday, June 1st) at 3:00 p.m., at the St. Andrew's Club & Conference Centre, 150 King Street West. MORE>>
CYNAPSUS ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
TORONTO, ONTARIO--(Marketwire - May 31, 2011) - Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, today announced the results of its Annual and Special Meeting of Shareholders held earlier in the day, on May 31, 2011. MORE>>
TORONTO, ONTARIO--(Marketwire - May 31, 2011) - Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, today announced the results of its Annual and Special Meeting of Shareholders held earlier in the day, on May 31, 2011. MORE>>
BIOSIGN APPOINTS THREE NEW MEMBERS TO BOARD OF DIRECTORS
TORONTO, May 27, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO, "Biosign") announced today the appointment to its board of directors of Dr. Harold S. Koplewicz, Jason D. Meretsky, and Former Senator Alfonse D'Amato.
TORONTO, May 27, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO, "Biosign") announced today the appointment to its board of directors of Dr. Harold S. Koplewicz, Jason D. Meretsky, and Former Senator Alfonse D'Amato.
"We are pleased to welcome back Senator D'Amato and be joined by our new members, Dr. Koplewicz and Mr. Meretsky", said David Silver, the company's Chairman. "As Biosign embarks on an exciting period of change and growth, attracting a diverse range of leadership for our Board and management team is critical to our success". MORE>>
Subscribe to:
Posts (Atom)